Post-ET Myelofibrosis
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (NCT06479135) | Kartos Therapeutics, Inc. | 2024-06-03 |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (NCT05280509) | Telios Pharma, Inc. | 2022-06-09 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (NCT04640532) | Kartos Therapeutics, Inc. | 2020-11-17 |
Track Post-ET Myelofibrosis automatically
Every clearance here is in the API, with alerts when new ones post.